Checkpoint Therapeutics jumps

Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn an additional $0.7 with the CVR.
Sun Pharma Acquires Checkpoint Therapeutics for $355 Million
Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and locally advanced cutaneous squamous cell carcinoma.
Checkpoint Therapeutics jumps after deal to be acquired by Sun Pharma
Shares of Checkpoint Therapeutics (CKPT) have jumped $1.59, or 64%, to $4.06 in Monday morning trading after the company and Sun Pharmaceutical
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million
India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics, a U.S.-based immunotherapy and targeted oncology company, for $355 million. The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through several acquisitions and collaborations.
India's Sun Pharma buys onco-derma firm Checkpoint Therapeutics for $355M
India's pharma giant Sun Pharma to acquire Checkpoint Therapeutics (NASDAQ:CKPT)—an immunotherapy and targeted oncology company—for an upfront cash payment of $355M. The deal involves an upfront cash payment of $4.
Sun Pharma agrees to acquire Checkpoint Therapeutics
Sun Pharmaceutical has agreed to acquire Checkpoint Therapeutics for an aggregate consideration of up to $355m upfront.
Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma
Shares of Checkpoint Therapeutics surged in premarktet trading Monday after the immunotherapy and targeted oncology company agreed to be acquired by Indian pharmaceutical giant Sun Pharmaceutical Industries.
Sun Pharma to acquire US oncology compony for over Rs 3,000 crore
Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhance Sun Pharma's specialty portfolio, including UNLOXCYT,
HC Wainwright Reaffirms Neutral Rating for Checkpoint Therapeutics (NASDAQ:CKPT)
Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “neutral” rating reissued by research analysts at HC ...
Fierce Pharma2d
On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M
Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...
Checkpoint Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Checkpoint Therapeutics (CKPT) to Neutral from Buy with a price target of $4.10, down from $20, following the ...
Checkpoint Therapeutics’ (CKPT) Hold Rating Reaffirmed at Lake Street Capital
Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “hold” rating reiterated by equities research ...
Sun Pharma to Acquire Checkpoint Therapeutics
(Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire ...
Labiotech.eu22h
Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Checkpoint Therapeutics, Inc. Buyout
Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities ...
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale To Sun Pharma
On March 9, 2023, Checkpoint announced the deal with Sun Pharma, under which shareholders will receive $4.10 per share in cash (or a total of $355 million). if cosibelimab receives EU approval within ...